Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane +19 more
wiley +1 more source
From Biomaterials to Biological State Engineering: Reframing Advanced Wound Dressings as Adaptive Therapeutic Interfaces in Translational Medicine. [PDF]
Urbanowicz T +6 more
europepmc +1 more source
Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro +6 more
wiley +1 more source
Historical Biography for Translational Medicine: an important genre for translational science
Simon W Rabkin
doaj +1 more source
From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine. [PDF]
Qiao L +9 more
europepmc +1 more source
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw +5 more
wiley +1 more source
Advances in Molecular and Translational Medicine: 2nd Edition. [PDF]
Boccellino M.
europepmc +1 more source
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit +11 more
wiley +1 more source
From local tissue repair to systemic precision orthopaedics: recent advances in musculoskeletal regeneration and translational medicine. [PDF]
Lu S, Shi Q, Yang H.
europepmc +1 more source
Founding Editorial: Neuro‐Drug Discovery
Neuro-Drug Discovery, EarlyView.
Wenbin Li
wiley +1 more source

